Sarepta Therapeutics, Inc. (LON:0L35)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.49B +4.8% |
| Revenue (ttm) | 1.49B -20.4% |
| Net Income | -103.05M |
| EPS | -0.99 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 9.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,011 |
| Open | 18.30 |
| Previous Close | 18.19 |
| Day's Range | 18.03 - 18.91 |
| 52-Week Range | 14.35 - 25.34 |
| Beta | 0.26 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 4, 2026 |
About Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; ... [Read more]
News
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duch...
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Gr...
Sarepta Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Leadership outlined a dual focus on supporting marketed products and advancing a differentiated pipeline, with key data readouts for FSHD and DM1 expected in the second half of the year. ELEVIDYS shows signs of stabilization, while the PMO franchise remains robust despite upcoming competition.
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns about the prospects of similar therapie...
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholar...
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK CITY and NEW ORLEANS, Sept. 4, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi...
Sarepta Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw operating profitability, strong cash growth, and stable Duchenne therapy demand. Revenue guidance was narrowed, with second-half sales expected to dip before a rebound in 2027 as commercial initiatives gain traction. Multiple regulatory and clinical milestones are upcoming.
Sarepta Therapeutics Quarterly report: Q2 2026
Sarepta Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Sarepta Therapeutics Earnings release: Q2 2026
Sarepta Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Sarepta Therapeutics Slides: Q2 2026
Sarepta Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously ap...
Sarepta names former Abbvie president as CEO as Ingram retires
Sarepta Therapeutics said on Monday it appointed former Tessera Therapeutics CEO Michael Severino its chief executive, effective July 28. The longtime AbbVie executive, will succeed Doug Ingram.
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as c...
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nas...
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT)
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) against ce...
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA...
Sarepta Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Leadership transition is underway with a focus on strategic priorities for 2026, including ELEVIDYS stabilization, pipeline advancement, and financial strength. Strong financials, robust pipeline progress, and positive regulatory outlook support growth, with pivotal siRNA trials planned for next year.
Sarepta Therapeutics Transcript: AGM 2026
The meeting approved all five proposals, including director elections, executive compensation, and new equity plans. Shareholders raised questions about board composition, CEO succession, and compensation, with the board emphasizing stability and ongoing performance improvements.
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the ...
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi...
Sarepta Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw stabilized operations, strong cash reserves, and positive operating profit, with ELEVIDYS and PMO franchises performing steadily. Promising siRNA pipeline data and expanded commercial initiatives support full-year guidance of $1.2–$1.4 billion.
Sarepta Therapeutics Quarterly report: Q1 2026
Sarepta Therapeutics has published its Q1 2026 quarterly earnings report on May 6, 2026.
Sarepta Therapeutics Earnings release: Q1 2026
Sarepta Therapeutics released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.